Graves病患者经131I治疗后血浆和红细胞锌含量的变化及其临床意义

为研究Graves病(GD)患者经^131I治疗后血浆和红细胞锌(Zn)含量的变化及其临床意义，采用原子吸收分光光谱法(AAS)和放射免疫分析法(Rn)分别检测了40例GD患者、20例经^131I治疗后甲状腺功能恢复至正常水平GD患者与30名健康人血浆和红细胞Zn的含量以及血浆甲状腺激素水平。结果表明，GD组红细胞Zn含量明显低于对照组(P＜0．01)；血浆Zn含量虽略低于对照组，但无统计学意义(P＜0．05)；且Zn与FT4呈明显负相关(P＜0．01)、与TSH呈正相关(P＜0．05)。GD治疗缓解组红细胞Zn明显高于治疗前(P＜0．01)，血浆Zn明显低于治疗前(P＜0．05)；红细胞Zn检测GD的敏感性与特异性分别为95．0％与96．7％。提示GD患者存在红细胞Zn含量改变，甲状腺激素可能干扰红细胞Zn的代谢，同时测定红细胞Zn可作为GD的临床诊断、治疗以及疾病转归的参考指标。

Clinical Significance and Changes of Zinc in Serum and Erythrocytes of Patients with Graves Disease after 131I Therapy

To study clinical significance and changes of Zn in serum and erythrocytes of after 131 I therapy in patients with Graves disease,the content of Zn in serum and erythrocytes and the levels of serum thyroid hormones were determined with atom absorption spectrophotometry (AAS)and radioimmunoassay(RIA)in 40 cases of GD,20 cases of GD patients aftert 131 I herapy(in euthyroid state)and 30 normal controls.The results showed that without treatment the content of Zn in erythrocytes was significantly lower in GD patients than those in normal controls(P>0.01),but the content of Zn in serum didn't show statistical differences compared to thd normal controls(P>0.05).The content of Zn in erythrocytes was negative correlated to FT 4(P<0.01)and was positive correlated to TSH(P<0.05).The content of Zn in erythrocytes after treatment was significantly higher(P<0.01),and Zn in serum was significantly lower(P<0.05)than those before treatment.The sensitivity and specificity of Zn in erythrocyts was 95.0% and 96.7% in detecting GD.It indicates the Zn in erythrocytes might be adversely influenced by excess of thyroid hormone in patients with GD,and the Zn in erythrocytes may be served as a diagnotic index for GD.